

Alexa B Kimball

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2109916/alexa-b-kimball-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

262
papers

13,618
citations

58
h-index

111
g-index

283
ext. papers

16,120
ext. citations

4.5
avg, IF

6.55
L-index

#	Paper	IF	Citations
262	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). <i>Lancet, The</i> , 2008 , 371, 1665-74	4.0	1296
261	Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 106-15	4.5	685
260	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , 2015 , 373, 1318-28	59.2	530
259	IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. <i>Journal of Experimental Medicine</i> , 2006 , 203, 2577-87	16.6	524
258	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 403-417	4.5	476
257	National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 1031-42	4.5	329
256	The psychosocial burden of psoriasis. <i>American Journal of Clinical Dermatology</i> , 2005 , 6, 383-92	7.1	324
255	Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. <i>New England Journal of Medicine</i> , 2016 , 375, 422-34	59.2	324
254	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. <i>Lancet, The</i> , 2017 , 390, 276-288	4.0	302
253	Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. <i>Annals of Internal Medicine</i> , 2012 , 157, 846-55	8	255
252	Quantifying the harmful effect of psoriasis on health-related quality of life. <i>Journal of the American Academy of Dermatology</i> , 2002 , 47, 512-8	4.5	207
251	Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 864-71	27.4	202
250	Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 1144-50	4.5	181
249	Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. <i>Archives of Dermatology</i> , 2008 , 144, 200-7		179
248	The US dermatology workforce: a specialty remains in shortage. <i>Journal of the American Academy of Dermatology</i> , 2008 , 59, 741-5	4.5	176
247	Text-message reminders to improve sunscreen use: a randomized, controlled trial using electronic monitoring. <i>Archives of Dermatology</i> , 2009 , 145, 1230-6		173
246	Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. <i>British Journal of Dermatology</i> , 2017 , 177, 1401-1409	4	157

245	Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2006 , 55, 607-13	4.5	149
244	Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, 457-65	4.5	139
243	Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 1535-45	4.6	137
242	Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. <i>Dermatology</i> , 2008 , 217, 27-37	4.4	135
241	Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 333-7	4.6	134
240	Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2012 , 66, 369-75	4.5	132
239	The response of skin disease to stress: changes in the severity of acne vulgaris as affected by examination stress. <i>Archives of Dermatology</i> , 2003 , 139, 897-900		131
238	Psoriasis: is the impairment to a patient's life cumulative?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24, 989-1004	4.6	127
237	Hidradenitis suppurativa: Epidemiology and scope of the problem. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, S4-7	4.5	123
236	North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 76-90	4.5	116
235	Risks of developing psychiatric disorders in pediatric patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, 651-7.e1-2	4.5	114
234	Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1866-73		111
233	Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. <i>British Journal of Dermatology</i> , 2014 , 171, 1434-42	4	110
232	The dermatology workforce shortage. <i>Journal of the American Academy of Dermatology</i> , 2004 , 50, 50-4	4.5	110
231	Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2012 , 66, 742-51	4.5	105
230	North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 91-101	4.5	102
229	Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. <i>JAMA Dermatology</i> , 2013 , 149, 25-32	5.1	98
228	Hidradenitis suppurativa. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 18	5.1	95

227	Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. <i>British Journal of Dermatology</i> , 2012 , 166, 861-72	4	95
226	Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 19-31	4.6	95
225	Topical vitamins, minerals and botanical ingredients as modulators of environmental and chronological skin damage. <i>British Journal of Dermatology</i> , 2003 , 149, 681-91	4	92
224	Systemic associations of hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, S27-35	4.5	91
223	Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1399-1407	9.5	91
222	Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). <i>British Journal of Dermatology</i> , 2014 , 171, 137-47	4	89
221	Economic burden of comorbidities in patients with psoriasis is substantial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 157-63	4.6	83
220	The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. <i>British Journal of Dermatology</i> , 2011 , 165, 1066-73	4	81
219	The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2009 , 61, 405-10	4.5	81
218	Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, 76-85	4.5	80
217	HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, 989-94	4.6	79
216	Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. <i>Drug Safety</i> , 2016 , 39, 755-62	5.1	78
215	Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, Continental Indian and African American women. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 1054-60	4.6	77
214	Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002. <i>Current Medical Research and Opinion</i> , 2006 , 22, 989-1000	2.5	76
213	Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2007 , 18, 341-50	2.8	72
212	Acne vulgaris in women: prevalence across the life span. <i>Journal of Women's Health</i> , 2012 , 21, 223-30	3	70
211	Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. <i>British Journal of Dermatology</i> , 2004 , 151, 381-7	4	70
210	The Impact of Administrative Burden on Academic Physicians: Results of a Hospital-Wide Physician Survey. <i>Academic Medicine</i> , 2017 , 92, 237-243	3.9	69

209	Who else is providing care in dermatology practices? Trends in the use of nonphysician clinicians. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 211-6	4.5	65
208	Psoriasis epidemiology: the interplay of genes and the environment. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 287-9	4.3	64
207	Cutaneous effects of BRAF inhibitor therapy: a case series. <i>Annals of Oncology</i> , 2013 , 24, 530-537	10.3	60
206	Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 851-61.e4	4.5	59
205	Update on biologic safety for patients with psoriasis during pregnancy. <i>International Journal of Women's Dermatology</i> , 2017 , 3, 21-25	2	58
204	Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities. <i>American Journal of Medicine</i> , 2014 , 127, 1148-53	2.4	56
203	Pediatric Psoriasis Comorbidity Screening Guidelines. <i>JAMA Dermatology</i> , 2017 , 153, 698-704	5.1	54
202	The impact of psoriasis on pregnancy outcomes. <i>Journal of Investigative Dermatology</i> , 2012 , 132, 85-91	4.3	54
201	OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 115-22	4.5	51
200	Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. <i>Archives of Dermatology</i> , 2002 , 138, 1341-6		51
199	Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2016 , 175, 157-62	4	51
198	Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 70-80	4.5	51
197	Increased diagnosis of thin superficial spreading melanomas: A 20-year study. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, 387-94	4.5	49
196	Striae gravidarum. <i>Clinics in Dermatology</i> , 2006 , 24, 97-100	3	49
195	Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and N-acetyl glucosamine: results of a randomized, double-blind, vehicle-controlled trial. <i>British Journal of Dermatology</i> , 2010 , 162, 435-41	4	48
194	Prevalence and Risk of Inflammatory Bowel Disease in Patients with Hidradenitis Suppurativa. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 1060-1064	4.3	47
193	Latitude and psoriasis prevalence. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, 870-873	4.5	47
192	Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, 52-62	4.5	47

191	Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 117-122	4.5	46
190	Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. <i>Value in Health</i> , 2008 , 11, 400-7	3.3	45
189	Cutaneous manifestations of thyroid disease. <i>Clinics in Dermatology</i> , 2008 , 26, 283-7	3	45
188	Few Medicaid and uninsured patients are accessing dermatologists. <i>Journal of the American Academy of Dermatology</i> , 2006 , 55, 1084-8	4.5	45
187	Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial. <i>British Journal of Dermatology</i> , 2014 , 171, 1215-9	4	44
186	A single-blinded, randomized, controlled clinical trial evaluating the effect of face washing on acne vulgaris. <i>Pediatric Dermatology</i> , 2006 , 23, 421-7	1.9	44
185	Clinical Goals and Barriers to Effective Psoriasis Care. <i>Dermatology and Therapy</i> , 2019 , 9, 5-18	4	44
184	Psoriasis and psoriatic arthritis: separate or one and the same?. <i>British Journal of Dermatology</i> , 2007 , 157, 850-60	4	42
183	Accessibility to air travel correlates strongly with increasing melanoma incidence. <i>Melanoma Research</i> , 2006 , 16, 77-81	3.3	42
182	Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. <i>British Journal of Dermatology</i> , 2019 , 180, 1039-1049	4	41
181	Meta-analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgaris. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 450-9	4.5	40
180	Using the Physician Global Assessment in a clinical setting to measure and track patient outcomes. <i>JAMA Dermatology</i> , 2015 , 151, 375-81	5.1	40
179	Quality of life and treatment satisfaction among patients with psoriasis and psoriatic arthritis and patients with psoriasis only : results of the 2005 Spring US National Psoriasis Foundation Survey. <i>American Journal of Clinical Dermatology</i> , 2008 , 9, 111-7	7.1	40
178	Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 333-339	4.6	40
177	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. <i>British Journal of Dermatology</i> , 2018 , 179, 615-622	4	39
176	New antifungal therapies for the treatment of onychomycosis. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 727-34	5.9	39
175	Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09. <i>British Journal of Dermatology</i> , 2014 , 170, 366-73	4	38
174	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 936-945	4.5	38

173	Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. <i>British Journal of Dermatology</i> , 2014 , 170, 705-15	4	37
172	Self-reported acne severity, treatment, and belief patterns across multiple racial and ethnic groups in adolescent students. <i>Pediatric Dermatology</i> , 2010 , 27, 446-52	1.9	37
171	Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. <i>American Journal of Clinical Dermatology</i> , 2011 , 12, 51-62	7.1	35
170	Longer-term impact of cardiology e-consults. <i>American Heart Journal</i> , 2016 , 173, 86-93	4.9	34
169	Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 190-2	4.5	33
168	Briakinumab. <i>Expert Opinion on Biological Therapy</i> , 2009 , 9, 1107-13	5.4	33
167	Fate of manuscripts declined by the Journal of the American Academy of Dermatology. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 632-5	4.5	31
166	Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 114-119	4.5	31
165	Pregnancy outcomes in psoriasis: why do we know so little?. <i>Journal of the American Academy of Dermatology</i> , 2009 , 61, e5-8	4.5	30
164	Patient navigation based on predictive modeling decreases no-show rates in cancer care. <i>Cancer</i> , 2015 , 121, 1662-70	6.4	29
163	Striae and pelvic relaxation: two disorders of connective tissue with a strong association. <i>Journal of Investigative Dermatology</i> , 2006 , 126, 1745-8	4.3	29
162	Age-induced and photoinduced changes in gene expression profiles in facial skin of Caucasian females across 6 decades of age. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 29-39.e7	4.5	29
161	Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States. <i>British Journal of Dermatology</i> , 2015 , 173, 1183-90	4	28
160	Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. <i>Journal of the American Academy of Dermatology</i> , 2011 , 64, 263-74	4.5	28
159	Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 1156-1161	4.5	28
158	Cumulative life course impairment: evidence for psoriasis. <i>Current Problems in Dermatology</i> , 2013 , 44, 82-90		27
157	Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity. <i>Journal of Dermatological Treatment</i> , 2013 , 24, 255-60	2.8	27
156	Controlled nail trephination for subungual hematoma. <i>American Journal of Emergency Medicine</i> , 2006 , 24, 875-7	2.9	27

155	Dermatology: a unique case of specialty workforce economics. <i>Journal of the American Academy of Dermatology</i> , 2003 , 48, 265-70	4.5	27
154	What causes hidradenitis suppurativa ?-15 years after. <i>Experimental Dermatology</i> , 2020 , 29, 1154-1170	4	27
153	Management of hidradenitis suppurativa wounds with an internal vacuum-assisted closure device. <i>Plastic and Reconstructive Surgery</i> , 2014 , 133, 370e-377e	2.7	26
152	OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2013 , 68, 756-64	4.5	26
151	US dermatology residents' satisfaction with training and mentoring: survey results from the 2005 and 2006 Las Vegas Dermatology Seminars. <i>Archives of Dermatology</i> , 2008 , 144, 896-900		26
150	The Comorbidity Burden of Hidradenitis Suppurativa in the United States: A Claims Data Analysis. <i>Dermatology and Therapy</i> , 2018 , 8, 557-569	4	26
149	Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years. <i>Journal of Drugs in Dermatology</i> , 2018 , 17, 826-832 ^{2.2}		26
148	Gender and parenting significantly affect work hours of recent dermatology program graduates. <i>Archives of Dermatology</i> , 2004 , 140, 191-6		25
147	Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 523-5	4.5	24
146	Targeted Reminder Phone Calls to Patients at High Risk of No-Show for Primary Care Appointment: A Randomized Trial. <i>Journal of General Internal Medicine</i> , 2016 , 31, 1460-1466	4	24
145	Psoriasis prevalence among the 2009 AAD National Melanoma/Skin Cancer Screening Program participants. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 680-5	4.6	24
144	Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients. <i>JAAD Case Reports</i> , 2020 , 6, 99-102	1.4	23
143	The validity of the diagnostic code for hidradenitis suppurativa in an electronic database. <i>British Journal of Dermatology</i> , 2014 , 171, 338-42	4	23
142	Psoriasis and Cardiovascular Disease. <i>Medical Clinics of North America</i> , 2015 , 99, 1227-42	7	21
141	Health disparities among different ethnic and racial middle and high school students in sun exposure beliefs and knowledge. <i>Journal of Adolescent Health</i> , 2010 , 47, 106-9	5.8	21
140	Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa. <i>Journal of Dermatological Treatment</i> , 2018 , 29, 152-164	2.8	20
139	Current guidelines for psoriasis treatment: a work in progress. <i>Cutis</i> , 2018 , 101, 10-12	0.4	20
138	Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. <i>British Journal of Dermatology</i> , 2019 , 181, 967-975	4	19

137	Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacy. <i>Journal of Dermatological Treatment</i> , 2015 , 26, 507-13	2.8	19
136	Eruptive xanthomas associated with olanzapine use. <i>Archives of Dermatology</i> , 2003 , 139, 1045-8		19
135	Impact of Endometriosis on Life-Course Potential: A Narrative Review. <i>International Journal of General Medicine</i> , 2021 , 14, 9-25	2.3	19
134	Skin carotenoid levels in adult patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 945-9	4.6	18
133	Acne and oral contraceptives: update on women's health screening guidelines. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 781-6	4.5	18
132	TNF- α inhibitors in the treatment of hidradenitis suppurativa. <i>Therapeutic Advances in Chronic Disease</i> , 2019 , 10, 2040622319851640	4.9	17
131	Counterpoint: analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. <i>Journal of the American Academy of Dermatology</i> , 2013 , 69, 818-819	4.5	17
130	Self-reported help-seeking behaviors and treatment choices of adolescents regarding acne. <i>Pediatric Dermatology</i> , 2013 , 30, 36-41	1.9	17
129	Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis. <i>Journal of Dermatological Treatment</i> , 2017 , 28, 716-721	2.8	17
128	Comorbidities of hidradenitis suppurativa. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2017 , 36, 55-57	1.4	17
127	Psoriasis and herpes simplex virus are highly stigmatizing compared with other common dermatologic conditions: A survey-based study. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 525-6	4.5	16
126	Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 294-301.e6	4.5	16
125	Diffuse morbilliform eruption after consumption of ginkgo biloba supplement. <i>Journal of the American Academy of Dermatology</i> , 2002 , 46, 145-6	4.5	16
124	Adalimumab alleviates skin pain in patients with moderate-to-severe hidradenitis suppurativa: Secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 1141-1143	4.5	16
123	Beyond the blot: cutting edge tools for genomics, proteomics and metabolomics analyses and previous successes. <i>British Journal of Dermatology</i> , 2012 , 166 Suppl 2, 1-8	4	15
122	A novel approach to administration of peptides in women: Systemic absorption of a GnRH agonist via transvaginal ring delivery system. <i>Journal of Controlled Release</i> , 2016 , 233, 19-28	11.7	15
121	Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 1098-1106	4.6	14
120	Chronic pain management in dermatology: a guide to assessment and nonopioid pharmacotherapy. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 563-73; quiz 573-4	4.5	14

119	Meta-analysis of randomized controlled trials using 5% benzoyl peroxide and clindamycin versus 2.5% benzoyl peroxide and clindamycin topical treatments in acne. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, e117-e119	4.5	14
118	Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. <i>British Journal of Dermatology</i> , 2020 , 182, 1359-1368	4	14
117	Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. <i>British Journal of Dermatology</i> , 2020 , 182, 180-189	4	14
116	Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	14
115	Itch intensity in moderate-to-severe plaque psoriasis versus atopic dermatitis: A meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 1198-1200.e1	4.5	13
114	Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1215-1218	4.5	13
113	Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream. <i>American Journal of Clinical Dermatology</i> , 2010 , 11, 275-83	7.1	13
112	Clobetasol propionate foam in the treatment of psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 1735-40	4	13
111	Biologic Treatment for Hidradenitis Suppurativa. <i>American Journal of Clinical Dermatology</i> , 2019 , 20, 625-638	7.1	12
110	The relative impact of psoriasis and obesity on socioeconomic and medical outcomes in psoriasis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 216-21	4.6	12
109	Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension. <i>Acta Dermato-Venereologica</i> , 2018 , 98, 98-102	2.2	12
108	Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 2254-2256	4.6	11
107	A single-blinded, randomized pilot study to evaluate the effect of exercise-induced sweat on truncal acne. <i>Pediatric Dermatology</i> , 2008 , 25, 126-8	1.9	11
106	Reporting of ethical review of clinical research submitted to the Journal of the American Academy of Dermatology. <i>Journal of the American Academy of Dermatology</i> , 2007 , 56, 279-84	4.5	11
105	Workforce characteristics of mohs surgery fellows. <i>Dermatologic Surgery</i> , 2004 , 30, 136-8; discussion 138	1.7	11
104	Getting under the Skin: Report from the International Psoriasis Council Workshop on the Role of Stress in Psoriasis. <i>Frontiers in Psychology</i> , 2016 , 7, 87	3.4	11
103	Systemic causes of hair loss. <i>Annals of Medicine</i> , 2016 , 48, 393-402	1.5	11
102	Adverse Reactions to Biologics in Psoriasis. <i>Current Problems in Dermatology</i> , 2018 , 53, 1-14		11

101	A measure of chronic quality of life predicts socioeconomic and medical outcomes in psoriasis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 249-254	4.6	10
100	Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1515-1522	4.6	10
99	Weight loss in obese patients with psoriasis can be successfully achieved during a course of phototherapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012 , 26, 1582-4	4.6	10
98	Skin sun-acne tutorial evaluation among middle- and high-school students in central New Jersey. <i>Journal of the American Academy of Dermatology</i> , 2007 , 56, 407-12	4.5	10
97	Rising educational debt levels in recent dermatology trainees and effects on career choices. <i>Journal of the American Academy of Dermatology</i> , 2006 , 54, 329-31	4.5	10
96	Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018 , 37, 182-189	1.4	10
95	Targeting IL-23: insights into the pathogenesis and the treatment of psoriasis. <i>Indian Journal of Dermatology</i> , 2010 , 55, 171-5	0.9	10
94	Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>JAMA Dermatology</i> , 2021 , 157, 301-306	5.1	10
93	Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data. <i>BMJ Open</i> , 2019 , 9, e030579	3	10
92	Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II. <i>Acta Dermato-Venereologica</i> , 2018 , 98, 932-937	2.2	10
91	Publication trends in hidradenitis suppurativa from 2008 to 2018. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1885-1889	4.6	9
90	Skin differences, needs, and disorders across global populations. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2008 , 13, 2-5	1.1	9
89	How low should you go: novel device for nail trephination. <i>Dermatologic Surgery</i> , 2006 , 32, 828-33	1.7	9
88	Cytarabine-induced acute generalized exanthematous pustulosis. <i>Journal of the American Academy of Dermatology</i> , 2002 , 47, 633-5	4.5	9
87	An assessment of the relative impact of hidradenitis suppurativa, psoriasis, and obesity on quality of life. <i>International Journal of Women's Dermatology</i> , 2018 , 4, 198-202	2	9
86	Genetic basis for skin youthfulness. <i>Clinics in Dermatology</i> , 2019 , 37, 312-319	3	8
85	Teaching empathy to undergraduate medical students using a temporary tattoo simulating psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, 93-9	4.5	8
84	Survey research in dermatology: guidelines for success. <i>Dermatologic Clinics</i> , 2009 , 27, 121-31, vi	4.2	8

83	Telehealth Use by Age and Race at a Single Academic Medical Center During the COVID-19 Pandemic: Retrospective Cohort Study. <i>Journal of Medical Internet Research</i> , 2021 , 23, e23905	7.6	8
82	Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy. <i>International Journal of Women's Dermatology</i> , 2016 , 2, 151-153	2	8
81	Examining the prior authorization process, patient outcomes, and the impact of a pharmacy intervention: A single-center review. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 1308-1318	4.5	8
80	Understanding the cost of dermatologic care: A survey study of dermatology providers, residents, and patients. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 609-617	4.5	7
79	Delivering value in dermatology: insights from skin cancer detection in routine clinical visits. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 310-3	4.5	7
78	Chronic pain management in dermatology: pharmacotherapy and therapeutic monitoring with opioid analgesia. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 575-82; quiz 583-4	4.5	7
77	Socioeconomic disability in psoriasis. <i>British Journal of Dermatology</i> , 2009 , 161, 1410-2	4	7
76	Long-term safety of biologics in dermatology. <i>Dermatologic Therapy</i> , 2009 , 22, 2-21	2.2	7
75	Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 2001-7	4	7
74	Practice patterns among osteopathic dermatologists in the United States. <i>Journal of the American Academy of Dermatology</i> , 2007 , 56, 524-5	4.5	7
73	An assessment of the cost-utility of therapy for psoriasis. <i>Therapeutics and Clinical Risk Management</i> , 2006 , 2, 325-8	2.9	7
72	Melanoma in Hong Kong between 1983 and 2002: a decreasing trend in incidence observed in a complex socio-political and economic setting. <i>Melanoma Research</i> , 2010 , 20, 427-30	3.3	7
71	Baseline patient-reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1302-1308	4.6	7
70	The temporal association between cutaneous T-cell lymphoma and psoriasis: implications for common biologic processes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, e31-e32	4.6	7
69	Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 579-590	7.1	6
68	Should We Leave the Skin Biopsies to the Dermatologists?. <i>JAMA Dermatology</i> , 2016 , 152, 371-2	5.1	6
67	Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>British Journal of Dermatology</i> , 2018 , 179, 984-986	4	6
66	Medical versus surgical dermatology: how much training do residents receive?. <i>Dermatologic Surgery</i> , 2006 , 32, 597	1.7	6

65	Investigating race and gender in age at onset of hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e139-e141	4.6	6
64	Metabolic dysfunction in human skin: Restoration of mitochondrial integrity and metabolic output by nicotinamide (niacinamide) in primary dermal fibroblasts from older aged donors. <i>Aging Cell</i> , 2020 , 19, e13248	9.9	6
63	Methotrexate shows benefit in a subset of patients with severe hidradenitis suppurativa. <i>International Journal of Women's Dermatology</i> , 2020 , 6, 159-163	2	5
62	Biologic therapies for the treatment of hidradenitis suppurativa. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 621-633	5.4	5
61	Future perspectives/quo vadis psoriasis treatment? Immunology, pharmacogenomics, and epidemiology. <i>Clinics in Dermatology</i> , 2008 , 26, 554-61	3	5
60	The dermatology life quality index (DLQI) provides qualitatively different information from the pasi. <i>Journal of the American Academy of Dermatology</i> , 2004 , 50, P156	4.5	5
59	Online communications among hidradenitis suppurativa patients reflect community needs. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 1760-1762	4.5	5
58	AB0912 Two-year efficacy and safety of guselkumab for treatment of moderate-to-severe psoriasis: phase 3 voyage 1 trial 2018 ,		5
57	Advances in the treatment of acne. <i>Journal of reproductive medicine, The</i> , 2008 , 53, 742-52		5
56	Acne Knowledge of Hispanic Parents of Teenagers with Mild to Moderate Acne. <i>Pediatric Dermatology</i> , 2016 , 33, e292-3	1.9	4
55	Survey on Clinician Perceptions and Practices Regarding Goals of Care Conversations. <i>Journal of Palliative Medicine</i> , 2016 , 19, 1215-1217	2.2	4
54	The spectrum of nephrocutaneous diseases and associations: Genetic causes of nephrocutaneous disease. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 231-44; quiz 245-6	4.5	4
53	The spectrum of nephrocutaneous diseases and associations: Inflammatory and medication-related nephrocutaneous associations. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 247-70; quiz 271-2	4.5	4
52	Specializing in accountability: strategies to prepare a subspecialty workforce for care delivery redesign. <i>Academic Medicine</i> , 2013 , 88, 1900-3	3.9	4
51	Re. major life-changing decisions and cumulative life course impairment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 246-246	4.6	4
50	Understanding patient engagement in psoriasis treatment. <i>British Journal of Dermatology</i> , 2018 , 178, 988-989	4	3
49	Performing research in pregnancy: Challenges and perspectives. <i>Clinics in Dermatology</i> , 2016 , 34, 410-5	3	3
48	Dermatology urgent care: enlisting help from primary care in triage decisions. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 838-9	4.5	3

47	OBSERVE-5, an Observational Post-Marketing Safety Surveillance Registry of Etanercept for the Treatment of Psoriasis: A Model for Studying New Psoriasis Therapies. <i>Psoriasis Forum</i> , 2010 , 16a, 3-7		3
46	Leadership workforce in academic dermatology. <i>Archives of Dermatology</i> , 2007 , 143, 948-9		3
45	Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 417-421	4.6	3
44	Expanding scope of dermatologic mid-level practitioners includes prescription of complex medication. <i>JAMA Dermatology</i> , 2015 , 151, 106-7	5.1	2
43	Real-time location systems, normative messaging and modifying clinician behavior: a pilot study. <i>Health Systems</i> , 2014 , 3, 165-172	2.3	2
42	Validation of a screening instrument for nephrogenic systemic fibrosis. <i>Arthritis Care and Research</i> , 2013 , 65, 637-42	4.7	2
41	A cost-effectiveness comparison of liquor carbonis distillate solution and calcipotriol cream in the treatment of moderate chronic plaque psoriasis. <i>Archives of Dermatology</i> , 2010 , 146, 919-22		2
40	Targeting the IL-12/IL-23 cytokine family in the treatment of psoriatic disease. <i>Expert Review of Dermatology</i> , 2008 , 3, 453-463		2
39	Ketoconazole 2% foam for treatment of seborrheic dermatitis. <i>Expert Review of Dermatology</i> , 2008 , 3, 15-21		2
38	A visit guide for hidradenitis suppurativa-Managing a complex disease in a busy clinic. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, e155-e160	4.5	2
37	Effects of TNF-alpha antagonism in patients with metabolic syndrome and psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, e152-e154	4.6	2
36	Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, e544-e547	4.6	1
35	Use of biologics in pregnancy: limitations stemming from clinical trials and registry experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, e276-e277	4.6	1
34	Pharmacoeconomics of Systemic and Biologic Therapy in Dermatology 2018 , 83-91		1
33	An evaluation of educational debt levels in dermatology residents and effects on career choices. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 1141-2	4.5	1
32	Dermatologic workforce on the Texas border: using burden on primary care as an outcome measure. <i>International Journal of Dermatology</i> , 2013 , 52, 506-7	1.7	1
31	Prevalence of skin disorders in patients seeking health care. <i>Mayo Clinic Proceedings</i> , 2013 , 88, 776	6.4	1
30	Psoriasis and latitude: Analytic approaches and future data needs. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, e59	4.5	1

29	Psoriasis and cardiovascular disease: another contribution in the hierarchy of evidence. <i>British Journal of Dermatology</i> , 2012 , 167, 1198-9	4	1
28	Association of systemic psoriasis therapies and incidence of myocardial infarction: reply from authors. <i>British Journal of Dermatology</i> , 2012 , 166, 233	4	1
27	Assessing dermatology board examination competence using questions distribution: a 12-year Brazilian experience. <i>International Journal of Dermatology</i> , 2010 , 49, 1080-2	1.7	1
26	Patient preferences for dermatology visits. <i>Journal of the American Academy of Dermatology</i> , 2009 , 61, 1083-4	4.5	1
25	Rethinking eligibility creep. <i>Journal of the American Academy of Dermatology</i> , 2008 , 59, 165-7; author reply 167	4.5	1
24	Treatment Satisfaction and Health-related Quality of Life among Individuals with Psoriasis: National Psoriasis Foundation Survey Findings. <i>Psoriasis Forum</i> , 2008 , 14a, 27-34		1
23	The Impact of Childhood Atopic Dermatitis on Life Decisions for Caregivers and Families.. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022 ,	4.6	1
22	Transcriptomic analysis of human skin wound healing and rejuvenation following ablative fractional laser treatment. <i>PLoS ONE</i> , 2021 , 16, e0260095	3.7	1
21	Burnout Among All Groups of Physicians-Mitigation Strategies for Dermatologists. <i>JAMA Dermatology</i> , 2020 , 156, 1049-1050	5.1	1
20	Psoriasis: Knowledge, attitudes and perceptions among primary care providers. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1421-1423	4.5	1
19	Plastic Surgical Management of Hidradenitis Suppurativa. <i>Plastic and Reconstructive Surgery</i> , 2021 , 147, 479-491	2.7	1
18	Assessment of treatment-seeking behaviour in patients with psoriasis. <i>British Journal of Dermatology</i> , 2018 , 179, 989-990	4	1
17	Hidradenitis suppurativa disease course during pregnancy and postpartum: a retrospective survey study. <i>British Journal of Dermatology</i> , 2021 , 185, 1072-1074	4	1
16	Hidradenitis suppurativa for the dermatologic hospitalist. <i>Cutis</i> , 2019 , 104, 276-280	0.4	1
15	Unerwünschte Wirkungen von Biologika bei Psoriasis. <i>Karger Kompass Dermatologie</i> , 2017 , 5, 195-199	0	0
14	Treatment of moderate to severe hidradenitis suppurativa. <i>Annals of Internal Medicine</i> , 2013 , 159, 72-3	8	0
13	High placebo rates in clinical trials: Is the problem scoring systems or drug efficacy?. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, e431	4.5	0
12	A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 1147-1161	4.1	0

11	A Closer Inspection of the Number Needed to Biopsy-Reply. <i>JAMA Dermatology</i> , 2016 , 152, 953	5.1
10	Reply to: "Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment". <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, e19-e20	4.5
9	Teachable Action for Leaders Committed to Improving Physician Work Life: Continuing Education. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 1455-6	6.4
8	The Utility of Laser Thermometry in Grading Plaque Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2015 , 1, 15-17	1.1
7	Skin carotenoid levels are not associated with risk of nonmelanoma skin cancer: response to "Supplement use and the risk of cutaneous squamous cell carcinoma". <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, 1071-2; author reply 1073	4.5
6	Impact of Film ("My SkinB on Fire: Living With Psoriasis") on Medical Student Education in Dermatology. <i>Journal of the Dermatology NursesoAssociation</i> , 2009 , 1, 190-194	0.2
5	Innovative care, medical research, and the ethics of informed consent. <i>Journal of the American Academy of Dermatology</i> , 2007 , 56, 330-2	4.5
4	Hidradenitis Suppurativa Epidemiology 2022 , 10-17	
3	Clinical Evaluation 2022 , 62-68	
2	Refining how we measure as we test: new insights using adalimumab in patients with hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 2342	4.6
1	Response to Letter to the Editor entitled: Rethinking biologic and pregnancy research: The importance of assessing postpartum immunosuppression of the infant. <i>International Journal of Women's Dermatology</i> , 2021 , 7, 510-511	2